Observational studyCardiovascular diabetology2025
Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project.
Observational study in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05626413 (Cardiovascular Disease and Diabetes in Silesian Patients), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cardiovascular Disease and Diabetes in Silesian Patients
Who cites it
8 citing papers in PubMed.
- Machine learning to identify novel bleeding and residual thromboembolic risks in patients on anticoagulation.Journal of thrombosis and thrombolysis · 2026Article
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- High inflammatory burden may link non-albuminuric diabetic kidney disease to carotid atherosclerosis.Cardiovascular diabetology · 2026Article
- Association of endothelial activation and stress index with all-cause and cardiovascular mortality in patients with diabetic kidney disease: a population-based prospective study.Diabetology & metabolic syndrome · 2026Article
- Literature-informed ensemble machine learning for three-year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model.Diabetes, obesity & metabolism · 2026Article
- Cardio-Reno-Microvascular Phenotypes and Multifactorial Cardiometabolic Target Achievement in Type 2 Diabetes.Journal of clinical medicine · 2026Article
- Objective tongue phenotyping identifies phenotypic heterogeneity in diabetic kidney disease: a dual-center clustering analysis.Frontiers in endocrinology · 2026Article
- Disease clusters and death trajectories in individuals with frailty: a prospective cohort study from the UK Biobank.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe impact of diabetic kidney disease (DKD) phenotype on the cardiovascular (CV) risk remains ambiguous.
methodsThis was a prospective, single-center study (The Silesia Diabetes-Heart Project, NCT05626413) of people with diabetes mellitus (DM). The primary outcome was a composite of CV events during a median follow up of 2.8 years (IQR 1.7; 4.0). Individuals were divided into groups based on DKD phenotypes [reduced estimated glomerular filtration rate (eGFR) (< 60 mL/min/1.73 m
resultsAmong 2306 people with DM (mean age 58 ± 18 years, 51.9% males) those with DKD had higher CV events risk (aHR 1.02, 95% CI 1.01-1.03) compared to those without DKD. People with reduced eGFR (aHR 1.78, 95% CI 1.19-2.67) and those with reduced eGFR and elevated UACR (aHR 1.60, 95% CI 1.08-2.37) were at higher risk of CV events compared to people with normal eGFR and UACR, while people with elevated UACR only (aHR 0.91, 95% CI 0.62-1.32) did not had the risk heightened. Among people with DKD less frequent prescriptions with sodium-glucose co-transporter 2 inhibitors and renin-angiotensin-aldosterone system inhibitors were observed (OR 0.38, 95% CI 0.29-0.49, p < 0.001 and OR 0.39, 95% CI 0.30-0.50, p < 0.001, respectively) compared with the ones without DKD.
conclusionPeople with DKD, with reduced eGFR or both reduced eGFR and elevated UACR, but not with elevated UACR alone, are at higher CV risk. Personalizing therapy based on clinic-based renal phenotyping can facilitate the initiation of CV disease modifying therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.